Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sona Nanotech Inc C.SONA

Alternate Symbol(s):  SNANF

Sona Nanotech Inc. is a nanotechnology life sciences company that has developed multiple methods for the manufacturing of various types of gold nanoparticles. The Company is engaged in the research and development of its technology for use in multiplex diagnostic testing platforms and biomedical applications. Its gold nanotechnologies are adapted for use in applications, as a safe and delivery system for multiple medical treatments, for the approval of various regulatory boards, including Health Canada and the Food and Drug administration (FDA). Its gold nanorod particles are manufactured without the use of CTAB (cetyltrimethylammonium), eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. The Company leverages its core proprietary gold nanorod (GNR) manufacturing technology and laboratory assets to focus on the development of diagnostic tests and biologic reagents, and the advancement of its GNR intellectual property.


CSE:SONA - Post by User

Comment by MikeyHon Sep 30, 2020 1:19pm
103 Views
Post# 31642474

RE:RE:RE:RE:RE:RE:RE:RE:ANTIGEN TESTS SEEKING HC APPROVAL

RE:RE:RE:RE:RE:RE:RE:RE:ANTIGEN TESTS SEEKING HC APPROVALYes, we have. What MRIGlobal produced was NOT A CLINICAL STUDY, no matter how many times you insist it was. These are laboratory studies, nothing more. If you don't believe me, read FIND's protocol summary which clearly explains the difference here: https://www.finddx.org/wp-content/uploads/2020/04/20200421-COVID-Ag-RDT-Evaluation-Synopsis.pdf

The primary objectives state:

1.1[Lab Evaluation] To determine the relative analytical sensitivity of COVID-19 antigen RDTs (index test) using contrived specimens: respiratory swab samples spiked with known quantities of cultured viral isolate.

1.2[Clinical Evaluation] To determine the diagnostic accuracy of COVID-19 antigen RDTs in patients presenting with influenza-like illness using upper respiratory tract specimens compared to gold-standard RT-PCR.

MRIGlobal performed a lab evaluation, which everyone seems to be relying on as '3rd party validation'. The only clinical data Sona has declared is the Saudi study. FIND would offer a route to validate this data clinically, hence my hope this happens.

Anyway, it's pointless arguing about this because you do not seem to understand this most  fundamental concept of developing a diagnostic. GLTA



<< Previous
Bullboard Posts
Next >>